Is MDGL or MGNX more undervalued in 2026?

CirclFi compares Madrigal Pharmaceuticals, Inc. (MDGL) and MacroGenics, Inc. (MGNX) using 13 institutional-grade valuation models. MDGL has a Quality of Company score of 6.9/10 while MGNX scores 6.2/10.

Which is a better buy — MDGL or MGNX?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do MDGL and MGNX valuations compare?

MDGL at $515.96 and MGNX at $4.21 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

MDGL vs MGNX Valuation Comparison 2026 — Intrinsic Value Analysis

MDGL

Biotechnology

Madrigal Pharmaceuticals, Inc.

Quality

6.9

out of 10

Value Trap

SAFE

Price

$515.96

Last close

Models

12/13

Active

MGNX

Biotechnology

MacroGenics, Inc.

Quality

6.2

out of 10

Value Trap

SAFE

Price

$4.21

Last close

Models

12/13

Active

Model-by-Model Comparison

Model	Type	MDGL Fair Value	MDGL Upside	MGNX Fair Value	MGNX Upside
Bayesian DCF	Intrinsic	$174.43	-66.2%	$1.10	-73.9%
Earnings Power Value	Intrinsic	$237.47	-53.7%	$9.04	+188.9%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for MDGL vs MGNX — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

MDGL vs MGNX — Which Stock Is More Undervalued?

MDGL scores higher with a 6.9/10 quality rating vs MGNX's 6.2/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Madrigal Pharmaceuticals, Inc. (MDGL) and MacroGenics, Inc. (MGNX) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

MDGL currently trades at $515.96 with a QOC of 6.9/10, while MGNX trades at $4.21 with a QOC of 6.2/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).